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Abstract
Background: To date, studies investigating the association between ACTN3 R577X and ACE I/D gene variants and
elite sprint/power performance have been limited by small cohorts from mixed sport disciplines, without
quantitative measures of performance. Aim: To examine the association between these variants and sprint time in
elite athletes.
Methods: We collected a total of 555 best personal 100-, 200-, and 400-m times of 346 elite sprinters in a large
cohort of elite Caucasian or African origin sprinters from 10 different countries. Sprinters were genotyped for ACTN3
R577X and ACE ID variants.
Results: On average, male Caucasian sprinters with the ACTN3 577RR or the ACE DD genotype had faster best 200-m
sprint time than their 577XX (21.19 ± 0.53 s vs. 21.86 ± 0.54 s, p = 0.016) and ACE II (21.33 ± 0.56 vs. 21.93 ± 0.67 sec,
p = 0.004) counterparts and only one case of ACE II, and no cases of ACTN3 577XX, had a faster 200-m time than the 2012
London Olympics qualifying (vs. 12 qualified sprinters with 577RR or 577RX genotype). Caucasian sprinters with the ACE
DD genotype had faster best 400-m sprint time than their ACE II counterparts (46.94 ± 1.19 s vs. 48.50 ± 1.07 s, p = 0.003).
Using genetic models we found that the ACTN3 577R allele and ACE D allele dominant model account for 0.92 % and
1.48 % of sprint time variance, respectively.
Conclusions: Despite sprint performance relying on many gene variants and environment, the % sprint time variance
explained by ACE and ACTN3 is substantial at the elite level and might be the difference between a world record and
only making the final.
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Background
Although the likelihood of becoming an elite sprint/
power athlete is likely influenced by genetic factors [1, 2]
only a handful of genes have been associated with sprint
performance. Currently the most promising candidate
gene is the ACTN3, which encodes the sarcomeric protein
α-actinin-3 in skeletal muscle fibres [3]. The expression of
α-actinin-3 protein is almost exclusively restricted to fast,
glycolytic, type 2X fibres, which are responsible for produ-
cing ‘explosive’, powerful contraction [4]. Homozygosity
for common null single nucleotide polymorphism
(577XX, rs1815739) in the ACTN3 gene results in
complete deficiency of the α-actinin-3 protein in an esti-
mated 18 % of humans worldwide [5], and the ACTN3 RR
genotype has been associated with elite sprint/power ath-
letic performance in several independent cohorts of elite
athletes [2].
A higher frequency of the ACTN3 577RR genotype
(and lower frequency of the α-actinin-3 deficient, 577XX
genotype) in elite sprint/power athletes (i.e., sprinters,
jumpers, and throwers) was originally found in a case
(athletes):control (non-athletes) association study with
Australian subjects [3]. This finding was independently
replicated in Finnish [6], Greek [7], Russian [8], Israeli
[9] and Japanese [10] national/international level ath-
letes. No Olympic-level sprinter has yet been identified
with the 577XX genotype [3, 7, 9, 11]. Taken together,
these association studies suggest that α-actinin-3 defi-
ciency is detrimental to optimal fast muscle function at
the extremes of sprint and power performance. In sup-
port of this, mice lacking α-actinin-3 (Actn3 knockout
mice, mimic the 577XX genotype in humans) demon-
strate a shift in the physiological and metabolic proper-
ties of ‘fast’ glycolytic muscle fibres (type 2B) towards a
slower, oxidative muscle phenotype (types 1 and 2A),
which are responsible for postural and endurance activ-
ities [12] and ACTN3 577XX humans show lower pro-
portion of fast-twitch muscle fibers [13, 14] and lower
levels of testosterone [15].
Another candidate gene associated with elite perform-
ance is the ACE I/D. Besides regulating blood pressure,
ACE may influence skeletal muscle function [16]. In-
deed, ACE catalyses the conversion of the vasocon-
strictor agent angiotensin I into, angiotensin II, which
not only as a more potent vasoconstrictor but also as a
muscle growth factor that is involved in overload-
induced muscle hypertrophy [17]. The ACE D allele is
usually associated with higher ACE activity, thereby po-
tentially resulting in higher angiotensin II levels [16] and
higher proportion of fast, glycolytic, type 2X muscle fi-
bres [18]; as such, this allele could theoretically favour
sprint/power-oriented performance. However, collect-
ively association studies performed with elite sprint/
power athletes are inconclusive [19–24].
One of the limitations of most studies above, investi-
gating the association between the ACTN3 R577X or the
ACE I/D genotype and sprint/power performance, is
grouping together sprint and power athletes from het-
erogeneous mixed sport disciplines and events (e.g.,
sprinters, jumpers, throwers, swimmers, and team sport
athletes). This approach, while understandable given the
very low number of world-class sprinters, reduces the
accuracy of the phenotype. Furthermore, to date, only
one report involving World-class sprinters of African an-
cestry [11], has studied the association between ACTN3
R577X and ACE I/D polymorphism and athletic status;
the lack of positive findings was attributable, at least
partly, to the very low frequency of the ACTN3 577XX
and ACE II genotypes in the African population, which
almost eliminates the possibility of detecting an associ-
ation. Here, we sought to address these limitations and
provide deeper insights into the influence of the ACTN3
R577X and the ACE I/D variants on sprint performance
by using a quantitative collaborative approach and by
studying the influence of genotype on actual sprint
performance.
Therefore, the aim of the present study was to examine
the association between the ACTN3 R577X and the ACE
I/D variants and 100-, 200-m and 400-m best personal
times, in a large, performance-homogenous, cohort of
elite Australian, Brazilian, Greek, Jamaican, Italian, Polish,
Russian, Lithuanian, Spanish and US sprinters.
Methods
Participants
A total of 555 personal best 100-m, 200-m and 400-m
sprint times of 346 elite pure sprinters from Australia,
Brazil, Greece, Jamaica, Italy, Lithuania, Poland, Russia,
Spain and US were analyzed (Tables 1 and 2). The
sprinters from Australia, Greece, Poland, Lithuania and
Russia were all Caucasians (189 male and 66 female)
whereas a total of 91 male Brazilian, Jamaican, US, Italian
and Spanish athletes were from African lineage. The
sprinters’ best personal records (tail wind < 2 m/s when
provided) in official competitions were found online
(www.iaaf.org) or provided by coaches or the athletes
themselves and independently corroborated (Tables 1
and 2). The sprinters’ best personal sprint times,
grouped according to ethnic-background (Caucasians /
Africans mixed linage athletes were excluded) and event
(100-, 200- or 400-m), were standardized and relatively
expressed to the relevant current World record. We in-
cluded only ‘pure’ sprinters with the personal sprint time
within 15 % of the current relevant World record of the
examined event. Thus, the following world records were
used to calculate the inclusion criterion: in the male
sprinters of African ancestry, 9.58 s in 100-m and 19.9 s in
200-m (current World record holder: Usain Bolt), and
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43.18-s in 400-m (current World record holder: Michael
Johnson); in female sprinters of African ancestry, 10.49 s
in 100 m and 21.34 s in 200-m (current World record
holder: Florence Griffith-Joyner); in the Caucasian male
sprinters, 9.99 s in 100-m (best record holder: Christophe
Lemaitre), 19.72 s in 200-m (best record holder: Pietro
Mennea), and 43.45 s in 400-m (best record holder:
Jeremy Wariner); and in female Caucasian sprinters,
10.77-s in 100-m (best record holder: Ivet Lalova) and
21.71 s and 47.60s in 200-m and 400-m respectively (best
World record holder: Marita Koch).
Genotyping
Genomic DNA was isolated from buccal epithelium, or
white blood cells. The Australian, Greek, Italian, Lithu-
anian, US, Jamaican, Russian (from St Petersburg) and
Spanish sprinters’ DNA samples were genotyped using the
polymerase chain reaction (PCR)-restriction fragment
length polymorphism (RFLP) method as previously de-
scribed [4].
The DNA samples of the Polish, Brazilian, Russian
(from Chelyabinsk), were genotyped in duplicates using
an allelic discrimination assay on a Step One Real-
Time PCR instrument (Applied Biosystems, Carlsbad,
California, USA) with Taqman® probes. To discri-
minate ACTN3 R577X (rs1815739) alleles, TaqMan®
Pre-Designed SNP Genotyping Assay was used (assay
ID: C_590093_1_), including appropriate primers and
fluorescently labeled (FAM and VIC) MGB™ probes to
detect the alleles.
Genotyping of the ACE I/D polymorphism, in all co-
horts, was carried out as previously described [25].
Statistical analysis
To compare the sprinters’ records between all geno-
types we used the one-way analysis of variance
(ANOVA). The Tukey’s post-hoc test was used to de-
termine statistical significant difference among the
genotype groups. The level of significance was set at
0.05. Using the Simple Interactive Statistical Analysis
website (SISA; www.quantitativeskills.com/sisa/) geno-
type interactions on sprint performance were further
assessed using correlation analysis as previously de-
scribed [26]. Briefly, three genetic models (additive
model and two dominant models assuming complete
dominance of each allele) were tested. The Additive
genetic model consisted of 0, 0.5 and 1, to represent
R allele homozygotes, RX heterozygotes and homozy-
gotes for the X allele, respectively; for the R allele
dominant or X allele dominant genetic models, the
corresponding values were 0, 0, 1 or 0, 1, 1, respect-
ively. The proportion of the genetic contribution to
phenotypic variance explained by each genetic model
was estimated by expressing r2 from the correlation
analyses (taken as an estimate of percentage variance
explained under the model) as a percentage of the
variance explained by genotype effects in the model-
free ANOVAs. This proportion was compared for
each model to predict the most accurate model
tested.
Results
The personal best 100-, 200- and 400-m sprint times
(±SD), according to the ACTN3 and ACE genotype and
distribution, are presented in Tables 1 and 2.
Table 1 The 100-m, 200-m and 400-m best sprint times (average±SD) in males according to ACTN3 R577X genotype distribution
Caucasians African Ancestry
Running event/Genotype RR RX XX RR +DD+ RX RR RX
100 m Male 10.55 ± 0.27 (n= 35) 10.58 ± 0.33 (n= 44) 10.77 ± 0.31 (n= 10) 10.56 ± 0.32 (n= 47) 10.26 ± 0.35 (n= 22) 10.28 ± 0.30 (n= 11)
200 m Male 21.19 ± 0.53 (n= 35) 21.29 ± 0.61 (n= 36) 21.86 ± 0.54* (n= 8) 21.17 ± 0.52 (n= 41) 20.53 ± 0.64 (n= 23) 20.98 ± 0.72 (n= 11)
400 m Male 46.90 ± 1.29 (n= 44) 47.41 ± 1.43 (n= 46) 47.55 ± 1.42 (n= 9) 46.82 ± 1.28 (n= 43) 46.49 ± 1.66 (n= 18) 47.29 ± 1.69 (n= 7)
*200-m (RR vs. RX vs. XX) P< 0.016
Table 2 The 100-m, 200-m and 400-m best sprint times (average±SD) in males according to ACE I/D genotype distribution
Caucasians African Ancestry
Running event/Genotype DD ID II XX + II + ID DD ID II
100 m Male 10.62 ± 0.32
(n = 33)
10.60 ± 0.29
(n = 28)
10.70 ± 0.30
(n = 13)
10.63 ± 0.29
(n = 42)
10.07 + 0.38
(n = 5)
10.27 + 0.32
(n = 13)
10.35 + 0.49
(n = 6)
200 m Male 21.33 ± 0.56
(n = 27)
21.25 ± 0.51
(n = 24)
21.93 ± 0.67**
(n = 11)
21.47 ± 0.64**
(n = 36)
20.53 + 0.70
(n = 9)
20.47 + 0.57
(n = 11)
21.16 + 0.42
(n = 4)
400 m Male 46.94 ± 1.19
(n = 35)
47.24 ± 1.40
(n = 43)
48.50 ± 1.07**
(n = 11)
47.49 ± 1.44**
(n = 58)
46.57 + 1.7
(n = 11)
47.08 + 1.29
(n = 7)
46.85 + 1.52
(n = 4)
**200-m (DD vs. ID vs. II) P < 0.004; **400-m (DD vs. ID vs. II) P < 0.003
**200-m (RR + DD + RX see Table 1 vs. XX + II + ID) P < 0.002; **400-m (RR + DD + RX see Table 1 vs. XX + II + ID) P < 0.001
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ACTN3 and ACE genotypes influence 200-m best-personal
sprint time in male athletes
In male Caucasian sprinters a significant association was
detected between ACTN3 genotype and 200 m best-
personal sprint time. Using Tukey’s Multiple Compari-
son Test both ACTN3 577RR, (−0.66, 95 % CI −0.20 to
−0.12) and 577RX (−0.56, 95 % CI −1.10 to −0.02) indi-
viduals were significantly faster than 577XX individuals
(P < 0.05). We found the R allele dominant model (RR/
RX vs. XX) had the best fit explaining 9.65 % of sprint
time (P = 0.005), compared to the additive (7.28 %, P =
0.01) and the X allele dominant model (2.77 %, P > 0.05)
in the correlation analysis. The percentage of the ob-
served variance (coefficient of determination, r2) ex-
plained by the ACTN3 genotype using this recessive
model was 0.92 %. The ACTN3 RR and ACTN3 RX
groups were not significantly different, indicating the
presence of one or two R allele does not have a dose de-
pendant effect on 200 m sprint speed in elite athletes
(Fig. 1a). In elite male African athletes (n = 92), there
was some evidence for a dose effect of the ACTN3 R al-
lele and 200 m sprint speed (Table 1). Using an unpaired
t-test, the ACTN3 RR individuals had (on average) a fas-
ter best-personal sprint time than ACTN3 RX individ-
uals (−0.45, 95 % CI, 0.95 to −0.04).
In male Caucasian sprinters a significant association was
detected between the ACE genotype and 200 m sprint
time. Using Tukey’s Multiple Comparison Test both ACE
DD, (−0.60, 95 % CI −1.09 to −0.11) and ACE ID (−0.68,
95 % CI −1.18 to −0.18) individuals had significantly faster
sprint time than ACE II individuals (P < 0.05). Again, cod-
ing the genotypes to test gene models found the D allele
dominant model (DD/ID vs. II) had the best fit explaining
16.4 % of variance (P = 0.001), compared to the additive
(8.0 %, P = 0.02) and the I allele dominant (1.2 %, P > 0.05)
model. The percentage of observed variance (coefficient of
determination, r2) explained by the ACE genotype using
this recessive model was 1.48 % (Fig. 1b).
ACTN3 and ACE genotypes influence 400-m best-personal
sprint time in elite male athletes
In male Caucasian sprinters a significant association was
detected between the ACE genotype and 400-m sprint
time. Using Tukey’s Multiple Comparison Test both
ACE DD, (−1.55, 95 % CI −2.61 to −0.48) and ACE ID
(−1.25, 95 % CI −2.29 to −0.21) individuals had signifi-
cantly faster sprint time than II individuals (P < 0.05).
Using genetic models we found, again, that the D allele
dominant model (DD/ID vs. II) had the best fit explain-
ing 11.39 % of 400 m sprint time (P = 0.001), compared
to the additive (9.78 %, P = 0.002) and I allele dominant
(3.97 %, P > 0.05). The percentage of observed variance
(coefficient of determination, r2) explained by the ACE
genotype using this recessive model was 1.48 %.
The ACE DD and ACE ID groups were not signifi-
cantly different in sprint time, indicating the presence of
one or two D allele does not have a dose dependant ef-
fect on 400-m best-personal sprint time in elite athletes
(Fig. 2b). No cases of ACE II male sprinters with a best-
personal 400-m sprint time faster than the Olympics
qualifying time (45.90s) were noted.
No genotype differences were detected in 100-m sprint
performance in both Caucasian and African ancestry
sprinters
There was no statistical significant difference in 100-m
best running times across the ACTN3 R577X and ACE
I/D genotypes (Figs. 3a and b). Caucasian (n = 66) fe-
males were assessed separately and showed similar run-
ning times to males, across genotypes.
No cumulative genotype effect on 200-m sprint
performance
In male Caucasian sprinters, a significant interaction
was detected between the genotype combination of
ACTN3 RR/RX and ACE DD with 200-m sprint speed
(Tables 1 and 2). Given we have found a positive
Fig. 1 a Individual 200-m running times (±SD) in male Caucasian sprinters according to their ACTN3 R577X genotype and the qualifying times
(QT) for the Olympic Games (20.65 s). b Individual 200-m running times (±SD) in male Caucasian sprinters according to their ACE I/D genotype
and the qualifying times (QT) for the Olympic Games (20.65 s)
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associations by independently examining the ACTN3
RR/RX and the ACE DD/ID genotypes in Caucasian
male 200-m sprint performance, we wondered whether
the combination of these positive genotypes would have
a cumulative benefit to performance. A genotype score
was applied (RR/RX = 2, DD/ID = 2, XX = 0, II = 0) and
plotted against 200 m performance time. An ideally
predisposed sprinter would receive 4; a less ideally pre-
disposed 2 and an adversely predisposed 0. Despite
hypothesising that the 200 m sprint time would be faster
with a higher genotype score, the slope was close to zero
(r2 = 0.02). Hence, there was no evidence for additive
effect of these variants on 200 m sprint speed
(Additional file 1).
Discussion
In this quantitative assessment of genotype with qualify-
ing time in 346 elite sprinters, we have shown that it is
rare for humans with the α-actinin-3 deficient (ACTN3
577XX) and the ACE II genotypes to qualify for the 200-
m, and 400-m competitions, respectively, at the Olympic
Games. From all male sprinters’ best personal times in-
cluded in this study, there were no cases of 577XX
sprinters who had faster best-personal running time than
2012 Olympic qualifying standard in 200-m (20.65 s),
and no cases of ACE DD sprinters who had best-
personal running time faster than 2012 Olympic
qualifying standard in 400-m (45.90s). Collectively, these
findings suggest that the ACTN3 577XX and the ACE II
genotypes are detrimental for 200- and 400-m sprint
performance respectively.
In the present study, we have addressed some of the
limitations inherent in previous athlete case–control
studies regarding the association between ACTN3 and
ACE genotypes and elite athletic performance. Firstly,
we have studied ten cohorts of elite sprinters, including
the fastest sprinters on earth. Consequently, the number
of ‘pure’ elite sprinters (n = 346) in the present study is
much larger compared to previous association studies,
and demonstrates the benefits of a collaborative ap-
proach that has been recommended in the field of exer-
cise genomics [1, 27, 28]. Secondly, previous reports
have grouped together sprint and power athletes from
mixed sports disciplines and events [3, 7–10, 28]. Here,
we have embraced a more stringent approach and included
only elite ‘pure’ sprinters whose main sporting event was
the 100-, 200- or 400-m sprint event. Furthermore, we set
explicit criteria (100-, 200- and 400-m best personal run-
ning times within 15 % from the World record) to ensure a
high performance level for the elite sprinters we studied.
Thirdly, we have analysed quantitative measure with re-
spect to ACTN3 and ACE genotypes to assess the genotype
effect size in both males and females separately. Only one
previous study has taken a similar approach with 100-m
Fig. 2 a Individual 400-m running times (±SD) in male Caucasian sprinters according to their ACTN3 R577X genotype and the qualifying times
(QT) for the Olympic Games (45.90s). b Individual 400-m running times (±SD) in male Caucasian sprinters according to their ACE I/D genotype
and the qualifying times (QT) for the Olympic Games (45.90s)
Fig. 3 a Individual 100-m running times (±SD) in male Caucasian sprinters according to their ACTN3 R577X genotype and the qualifying times
(QT) for the Olympic Games (10.24 s). b Individual 100-m individual running times (±SD) in male Caucasian sprinters according to their ACE I/D
genotype and the qualifying times (QT) for the Olympic Games (10.24-s)
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sprinters; a subgroup analysis of male Japanese track and
field athletes indicated that those harbouring the ACTN3
577XX genotype ran the 100-m sprint significantly slower
than their 577RX and 577RR counterparts [10]. However,
this study was limited by its sample size (n = 28) and stud-
ied only Japanese cohort.
The analyses we performed show that the male Cauca-
sian sprinters’ best personal times are influenced by both
ACTN3 and ACE genotypes in an event specific manner.
While similar trends were seen in African and female
athletes, we highlight that larger cohorts are urgently
needed for adequate genotype-performance assessments.
Our analyses on male Caucasian performances found
that 200- or 400-m (but not 100-m performance) is in-
fluenced by both the ACTN3 and the ACE genotypes.
Moreover, we showed that at the highest level of sprint-
ing competition (i.e., elite sprinters who had best-
personal sprint time faster than European or Olympic
qualifying times) there was no significant overlap of the
times for each genotype, suggesting that ‘every variable
counts’ for achieving world-class sprinting performance.
These findings, together with the separate results from
200- and 400-m sprints support the notion that per-
formance in the longer 200- and 400-m sprinting events
is influenced by both ACTN3 R577X and ACE ID
polymorphisms.
These genotype association differences may be related
to subtle differences in the physiological performance
demands of each event. In the 100-m race the athlete is
required to accelerate for most of the race before reach-
ing their absolute maximum velocity [29]. In longer
sprinting events (200- and 400-m) the acceleration phase
is relatively shorter, and rather, it is the ability to main-
tain the maximum velocity for a longer time period that
is the critical factor for winning the events [30]. Acceler-
ation relies on reaction time, centre of gravity of the
body relative to the blocks, frequency of step and step
length, while maintaining absolute maximal velocity re-
quires powerful cyclic muscle contractions and efficient
utilization of the energy systems (mostly lactic and ‘alac-
tic’ anaerobic systems) that are triggered at different
phases of the race [31]. Given the genotype-performance
associations at longer (200- and 400-m) distances, this
suggests their influence may lie greater effect on mus-
cle’s metabolic potential (switch from P/Cr to lactic an-
aerobic systems) with repeated powerful contractions.
The Actn3 knockout (KO) mouse has provided a pos-
sible explanation for the detrimental effect of α-actinin-3
deficient (577XX genotype) on elite sprinting perform-
ance. Mechanistic studies in the Actn3 KO mouse show
that this model mimics ACTN3 XX in humans. The
wild-type WT mice that express Actn3 (equivalent to
human RR/RX genotypes) prefer the anaerobic system
while Actn3 KO mice prefer the aerobic system.
Metabolically, the KO mice have significantly higher ac-
tivity of oxidative enzymes, and lower activity in en-
zymes of the anaerobic pathway. In addition, they have
enhanced glycogen accumulation due to lower glycogen
phosphorylase activity has been observed [32, 33]. Their
fast fibre properties shift towards a slower metabolic
profile which has been linked to increases in calcineurin
signalling activity [34] and altered calcium handling [35].
Overall this shift towards a slower physiological and
metabolic profile would be detrimental to sprint per-
formance in ACTN3 577XX humans [12, 32].
While a similar mechanistic model of the ACE geno-
type does not exist, a possible explanation for the meta-
bolic effect of the ACE genotype on sprint velocity
performance may be related to fibre-type differences.
Zhang et al. [18], has showed that the ACE II genotype
is associated with higher percentage of type I, aerobic-
oriented, muscle fibres while the ACE DD genotype
would be linked with a higher percentage of type 2X,
more anaerobic-oriented muscle fibres. While, more
studies are required to fully elucidate the mechanism be-
hind the potential association between the ACE genotype
and human elite sprint performance, it is interesting to
note that both ACTN3 and ACE variants may independ-
ently affect muscle fibre metabolism.
An additional exploration in the present study was
testing whether sprinters with the theoretical
‘favourable’ genotypes for ACE (DD/ID) and ACTN3
(RR/RX) had cumulative effects on performance
speed. While we did find a significant interaction for
the ACE and ACTN3 genotypes and sprint time (Ta-
bles 1 and 2), we have subsequently scored these vari-
ants and plotted against 200 m sprint time, and could
not detect evidence for additive effect on 200 m
sprint speed. Given the limited number of athletes
with the ACTN3 XX + ACE II genotype (and no dose
dependant allele differences in RR/RX and DD/ID), as
well as performance times that are approaching the
limits of human performance, testing for measurable
cumulative performance benefits in these elite cohorts
maybe difficult to achieve.
Despite no evidence for cumulative performance
benefits for the ACE and ACTN3 variants, both
genes have been repeatedly shown to be altered in
frequency in elite athletes compared to controls.
Given these associations, the notion that elite per-
formance is a polygenic trait by nature (e.g., a
phenotypic trait produced by multiple genes working
together), with a minor contribution of each variant
to the unique athletic phenotype, remains supported.
While probability of becoming an elite athlete is
thought to increase based upon having a greater
number of athletic-related alleles [36–38], our initial
scoring in male Caucasians demonstrates that it may
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be difficult to ascertain cumulative contributions to
performance.
Here, we have shown for the first time quantitatively
that the ACTN3 and ACE genotypes account for ~1-
1.5 % in sprint speed amongst elite male athletes. This
difference in sprint time is substantial at the elite level
and can be the difference between a world record and
only making the final 16. Despite this, the predictive
value of these tests remains limited. A substantial
amount of performance variation remains unaccounted
for and further research into both common and rare var-
iants is still required.
Conclusions
In conclusion, our multi-centre study has enabled us to
gain insights into the effect of ACTN3 and ACE geno-
types on elite sprinting performance. Both ACTN3
R577X and ACE ID polymorphisms modulate specific
sprint phenotypes and influence the athletic status at the
extremes of human performance. While the ACTN3
R577X polymorphism seems to be more influential to
200-m performance, the ACE ID polymorphism would
be more involved in the longer, 400-m sprint perform-
ance. With greater knowledge of both common and rare
performance variants these findings might have future
applications for identifying and coaching talented 200-
and 400-m sprinters.
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